- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03447951
A Study of PTS100 in Primary HCC Patients (OASES)
A Phase II Study to Assess the Safety and Efficacy of PTS100 in Primary Hepatocellular Carcinoma Patients Who Are Ineligible for Operation or Current Locoregional Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ben Liu
- Phone Number: 304 +886-2-2503-5282
- Email: ben.liu@gongwinbiopharm.com
Study Contact Backup
- Name: Eric Tu
- Phone Number: 303 +886-2-2503-5282
- Email: erictu@gongwinbiopharm.com
Study Locations
-
-
-
Taipei, Taiwan
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Ja Der Liang
-
Taipei City, Taiwan
- Recruiting
- Taipei Veterans General Hospital
-
Contact:
- Yi-Hsiang Huang, MD
-
Principal Investigator:
- Yi-Hsiang Huang, MD
-
Taipei City, Taiwan
- Recruiting
- Taipei Medical University Hospital
-
Contact:
- Wei-Yu Kao, MD
-
Principal Investigator:
- Wei-Yu Kao, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female, ≥ 20 years and ≤ 80 years of age.
Patients with clinically confirmed primary HCC following American Association for the Study of Liver Diseases (AASLD, Appendix 1) guidance:
- Cyto-histological evidence, or
- Coincident imaging evidence using computerized tomography (CT) or magnetic resonance imaging (MRI)
Based on investigator discretion, patients who are diagnosed at Barcelona Clinic Liver Cancer (BCLC) stage B and are ineffective or unsuitable for resection, immediate liver transplantation, Trans Arterial Chemoembolization (TACE), or current local ablative treatment and meet all of the following conditions at study entry:
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
- Child Pugh score class A or B.
- Patients with at least one measurable lesion with size ≥ 1 cm.
- Patients with cumulative total treated tumor volume ≤ 366 cm3 and ≤ 4 target tumors.
Patients with adequate bone marrow, liver and renal function within 28 days prior to study entry, as defined by the following:
- Hemoglobin > 10.0 g/dl.
- Absolute neutrophil count (ANC) > 1,500/mm3.
- Platelet count > 80k/mm3 correctable by component therapy.
- Albumin ≥ 3 g/dl.
- Total bilirubin < 2 mg/dL.
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5 x upper normal limit (UNL).
- Blood urea nitrogen (BUN) and serum creatinine < 1.5 x UNL.
- International normalized ratio (INR) < 1.5 or prothrombin time (PT) < 15 seconds.
- Patients with life expectancy > 3 months as judged by investigator.
- Patients who understand and comply to the study procedure and be willing to provide a written informed consent form.
Exclusion Criteria:
- Infiltrative HCC or tumor burden ≥ 50% of liver parenchyma.
- Patients with cumulative total treated tumor volume > 366 cm3 or more than 4 target tumors.
- Any target tumor exceeds 8.8 cm in diameter.
- The treated tumor is located in close proximity to another organ (e.g. gall bladder, liver capsule, diaphragm ) or major blood vessel and less than 0.5 cm in distance .
- Presence of metastasis or vascular invasion.
- Systemic chemotherapy treatment for HCC within 12 weeks prior to study entry.
- Major surgery within 4 weeks prior to study entry (e.g. thoracolaparotomy is not allowed, but noninvasive surgery, e.g. biopsy, is allowed).
- Use of any investigational drugs, biologics, or devices within 4 weeks prior to study entry or planned use during the course of study.
- Any other severe disease (e.g. active infection, uncontrolled diabetes mellitus, severe heart dysfunction or angina, gastric ulcer, active auto-immune disease) judged by the investigator to limit subject participation in the study.
- Female subjects who are pregnant or lactating. Women of childbearing potential must have a negative urine pregnancy test performed within seven days prior to the start of study drug and agree to practice medically acceptable contraceptive regimen from screening until at least 28 days after the study treatment. Patients who are postmenopausal for at least 1 year (> 12 months since the last menstrual cycle) or were surgically sterilized do not require the pregnancy test.
- Known or suspected allergy and/or hypersensitivity to any of the ingredients of PTS100.
- Any target lesion blocked by bile ducts or important blood vessels, judged by investigator, that is difficult to conduct intratumoral injection.
- Any condition, judged by investigator, that shows subjects are not suitable for participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PTS100 (Para-Toluenesulfonamide): 30%TTV
Total dose = 30% total tumor volume
|
A total dose of PTS100 in this study, the expected accumulated dose in the treatment duration, depends on the patient's tumour size.
For each patient, up to 4 tumors, each not exceeding 8.8 cm in diameter, are selected for treatment by the joint decision of the investigator and the radiologist.
The total dose is defined as the accumulated dose in treatment duration.
The total dose is assigned as 30% of TTV for each patient and maximum TTV should be less than 366 cm3.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: 4-week post treatment
|
To evaluate the efficacy, measured by objective response rate (ORR) of pooled treatment groups based on the modified RECIST (mRECIST) criteria at concluding visit.
|
4-week post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local disease control rate (LDCR)
Time Frame: 4-week post treatment
|
Local disease control rate (LDCR) of pooled treatment groups based on the modified RECIST (mRECIST) criteria at concluding visit.
|
4-week post treatment
|
Time to treated tumor progression (TTTTP)
Time Frame: 4-week post treatment, then every 2 months follow up with imaging will be continued for 12 months
|
Time to treated tumor progression (TTTTP) of pooled treatment groups
|
4-week post treatment, then every 2 months follow up with imaging will be continued for 12 months
|
Three-year overall survival (OS)
Time Frame: Time from first IP administration to patient death or to the date of 3 years after first IP administration
|
Three-year overall survival of pooled treatment groups
|
Time from first IP administration to patient death or to the date of 3 years after first IP administration
|
Time to tumor stage progression (TSP)
Time Frame: Time from first IP administration to every 2 months follow up with imaging will be continued for 12 months
|
Time to tumor stage progression of pooled treatment groups
|
Time from first IP administration to every 2 months follow up with imaging will be continued for 12 months
|
Difference in ORR between group 1 and group 2
Time Frame: 4-week post treatment
|
Difference in ORR between 20% group and 30% group at concluding visit
|
4-week post treatment
|
Difference in LDCR between group 1 and group 2
Time Frame: 4-week post treatment
|
Difference in LDCR between 20% group and 30% group at concluding visit
|
4-week post treatment
|
Difference in TTTTP between group 1 and group 2
Time Frame: 4-week post treatment to every 2 months follow up with imaging will be continued for 12 months
|
Difference in TTTTP between 20% group and 30% group at concluding visit
|
4-week post treatment to every 2 months follow up with imaging will be continued for 12 months
|
Incidence of Treatment-Emergent Adverse Events
Time Frame: Enrollment to 4-week post treatment
|
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.0
|
Enrollment to 4-week post treatment
|
FACT-Hep quality of life score
Time Frame: 4-week post treatment and every 2 months follow up will be continued for 12 months
|
To evaluate the health-related Quality of life, assessed by change in Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep, version 4, Traditional Chinese).
The FACT-Hep, version 4, Traditional Chinese Scale is a patient completed questionnaire consisting 45 items that assesses health related quality of life (HRQL) in HCC patients.
The FACT-Hep, version 4, Traditional Chinese consists of the 27-item FACT-G assessing generic HRQL concerns and 18-item Hepatobiliary Subscale assessing disease-specific issues.
Instrument scoring yields a range from 0 to 180 with higher scores representing better patient status.
This questionnaire should be completed by patient prior to any procedures being performed at the visit, if possible.
The form should then be checked by site staff for completeness.
|
4-week post treatment and every 2 months follow up will be continued for 12 months
|
EQ-5D-5L quality of life score
Time Frame: 4-week post treatment and every 2 months follow up will be continued for 12 months
|
To evaluate the health-related Quality of life, assessed by change in EuroQol 5 dimensions 5 level (EQ-5D-5L).
It comprises the same 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression).
Each dimension has 5 levels.
However, this results have no arithmetic properties and should not be used as a cardinal score.
This questionnaire should be completed by the patient prior to any procedure being performed at the visit, if possible.
The form should then be checked by site staff for completeness.
|
4-week post treatment and every 2 months follow up will be continued for 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ja Der Liang, National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GW-020202
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
Clinical Trials on Para-Toluenesulfonamide
-
PTS International Inc.Completed
-
PTS International Inc.Withdrawn
-
Florida International UniversityUniversity of Southern California; Universidad Peruana Cayetano HerediaRecruitingHIV Infections | Sexually Transmitted Diseases | Hiv | Sexual Behavior | Risk Reduction | Sexually Transmitted Infections (Not HIV or Hepatitis)United States
-
Columbia UniversityNational Cancer Institute (NCI)Unknown
-
First Affiliated Hospital of Zhejiang UniversityRecruitingColorectal Cancer | Synchronous Isolated Para-aortic Lymph Node MetastasisChina
-
Hospital Universitari Vall d'Hebron Research InstituteFundación Mutua MadrileñaCompletedOvarian Neoplasms | Endometrial NeoplasmsSpain
-
Arizona State UniversityCompletedDepression, Postpartum | Overweight and Obesity | Mother (Person)United States
-
University Hospital, MontpellierRecruitingInflammation | Low Back Pain | Degenerative Disc DiseaseFrance
-
Humanitas Hospital, ItalyRecruitingPancreas Adenocarcinoma | Pancreas Cancer | Pancreaticoduodenal LymphadenopathyItaly
-
University of Alabama at BirminghamRobert Wood Johnson Foundation; UAB Diabetes Research Center; UAB Nutrition Obesity... and other collaboratorsCompleted